Central Asian Journal of Medicine


Objective: To study the immunopathogenesis of HIV infection in patients with tuberculosis without lymphadenopathy, and to develop a strategy for early diagnosis and effective treatment. Materials and Methods: Clinical and immunological studies were conducted in 94 patients, who were divided into 2 groups of 47 people, depending on the stage of HIV infection. In turn, both groups were divided into subgroups: 22 patients with tuberculous lymphadenopathy, 25 - with HIV infection without tuberculous lymphadenopathy. The control group consisted of 21 practically healthy people. Results: In HIV infection, immune status disorders are more pronounced in patients with HIV + lymphadenopathy in combination with tuberculosis. HIV infection is accompanied not only by decrease in the number of T-lymphocytes, but also by their functional insufficiency. In HIV-infected individuals, the function of Th1-producing IFN-γ was disrupted at the IV stage of the disease and, consequently, the content of NK cells enhancing antibody formation was reduced. Conclusions: At laboratory study, HIV-infected individuals should undergo a clinical blood test with an expanded leukocyte formula. When formulating a clinical blood test, priority should be given to leukocytes and the first group of cells belonging to them, lymphocytes, since these protective cells are the first to suffer from infection with HIV.

First Page


Last Page



1. Popova A.A., Kravchenko A.V., Kozhevnikova G.M., Zimina V.N. Znacheniye dinamiki CD8+ SD28+ i CD4+ CD28+ u bol'nykh VICH-infektsiyey v sochetanii s tuberkulezom v protsesse lecheniya // Ter. arkh. – 2013. – №11. – S. 54-57. 2. Rabukhin A.Ye., Oleynik A.F. Immunologicheskaya neeffektivnost' ARVT pri VICH-infektsii. – M.: Meditsina, 2017. 3. Sokolova YU.V., Sizyakina L.P. Osobennosti sekretsii tsitokinov i ikh retseptsii v dinamike VICH-infektsii // Immunologiya. – 2007. – №7. – S. 324-327. 4. Sotnichenko S.A. Osobennosti immunopatogeneza i immunologicheskiye aspekty effektivnosti terapii pri VICH-sochetannom tuberkuleze: Dis. … kand. med. nauk. – Vladivostok, 2009. 5. Alimonti J.B., Ball T.B., Fowke K.R. Mechanisms of CD4+T lymphocyte cell death in human immunodeficiency virus infection and AIDS // J. Gen. Virol. – 2003. – Vol. 84. – P. 1649-1661. 6. Behbahani H. et al. Pro inflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection // J. Acquir. Immun. Defic. Syndr. – 2007. – Vol. 45, №1. – Р. 9-19. 7. Gazzola L., Tincati C., Bellistrı G.M. et al. The absence of CD4+ T cell count recovery despite receipt of virologicallysuppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options // Clin. Infect. Dis. – 2009. – Vol. 48. – P. 328-337. 8. Interim policy on collaborative TB/HIV activities. Clinico-epidemiological profile of HIV/TB coinfected patients in Vadodara. – Geneva: WHO, 2004. 9. Lee J.Y., Lee K.S., Jung K.J. et al. Pulmonary tuberculosis: CT and pathologic correlation // J. Comput. Ass. Tomogr. – 2000. – Vol. 24. – P. 691-698. 10. Lienhardt C., Rodriques L.C. Estimation of the impact of the human immunodeficiency virus infection on tuberculosis: tuberculosis risks revised? // Int. J. Tub. Lung Dis. – 1997. – Vol. 1, №3. – P. 196-204. 11. Marcus E., Ralph C., Murray J. et al. The CD95 Receptor: Apoptosis Revisited // Cell. – 2007. – Vol. 4. – P. 129. 12. Menezes Ah. IL-15 and HIV infection: lessons for immunotherapy and vaccination // Curr. HIV Res. – 2005. – Vol. 3, №3. –P. 261-270. 13. Mueller S.N., Langley W.A. Immunization with live attenuated influenza viruses altered NS1 proteins results in potent end protective memory CD8+T- cell responses // J. Virol. – 2013. – Vol. 84. – P. 1847-1855. 14. Silvin A., Manel N., Brenchley J.M. et al. HIV preferentially infects HIV-specific CD4+T cells // Nature. – 2015. – Vol. 417. – P. 95-98 15. UNAIDS. AIDS. Global report: UNAIDS report on the global AIDS epidemic 2010 // Joint United Nations Programme on HIV/AIDS, 2010. 16. WHO. Executive Summary. Global Tuberculosis Report, 2012. – Geneva, 2012. – P. 100.